ADXS - アドバクシス (Advaxis Inc.) アドバクシス

 ADXSのチャート


 ADXSの企業情報

symbol ADXS
会社名 Advaxis Inc (アドバクシス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アドバキシス(Advaxis Inc.)はリステリア・モノサイトゲネス(Lm)-リステリオリシン O(LLO)癌免疫療法の発見・開発・商業化に従事する臨床段階のバイオ技術会社である。これらの免疫療法は、抗原/アジュバント融合タンパク質を分泌する生きた弱毒化Lmバイオエンジニアリングを利用するプラットフォーム技術に基づいている。これらのLm-LLO株は、抗腫瘍T細胞免疫を刺激し、複数のアジュバントの等価物で免疫系を刺激・活性化するために、抗原提示細胞にアクセスして誘導すると同時に複数の機能を単一の免疫療法に統合し、同時にT細胞が腫瘍を排除することを可能にするために腫瘍微小環境における腫瘍保護を低下させる。Axalimogene filolisbacは、ヒトパピローマウイルス関連癌の治療用のリードLm-LLO免疫療法製品候補である。ADXS-PSAは、前立腺癌に関連する前立腺特異抗原(PSA)を標的とするLm-LLO免疫療法製品候補である。   アドバクシスは米国のバイオテクノロジ―企業。がんおよび感染症のための免疫療法の開発に従事。開発中の医薬品は、子宮頸がん、頭頸部がん、肛門がんの治療薬「ADXS-HPV」、前立腺がん向け「ADXS-PSA」、乳がん、胃がんや、ヒトにおける他のがんおよび犬の骨肉腫などのHER2過剰発現がんの治療薬「ADXS-cHER2」の開発を手掛ける。   
本社所在地 305 College Road East Princeton NJ 08540 USA
代表者氏名 David Sidransky デビッド・シドランスキー
代表者役職名 Independent chairman of the Board
電話番号 +1 732-545-1590
設立年月日 31929
市場名 NASDAQ National Market System
ipoyear ―年
従業員数
url www.advaxis.com
nasdaq_url https://www.nasdaq.com/symbol/adxs
adr_tso
EBITDA EBITDA(百万ドル) -74.67294
終値(lastsale) 0.792
時価総額(marketcap) 55040158.008
時価総額 時価総額(百万ドル) 58.15208
売上高 売上高(百万ドル) 6.69732
企業価値(EV) 企業価値(EV)(百万ドル) 18.71808
当期純利益 当期純利益(百万ドル) -71.17769
決算概要 決算概要 BRIEF: For the nine months ended 31 July 2018 Advaxis Inc. revenues decreased 52% to $4.9M. Net loss decreased 32% to $47.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative decrease of 79% to $3.6M (expense) Research and Development Expenses decrease of 17% to $36.1M (expense) Other decrease of 31% to $10.9M (expense).

 ADXSのテクニカル分析


 ADXSのニュース

   ADVAXIS MAKING BOLD STEPS IN NEW CANCER STUDIES AND AGREEMENT WITH COLUMBIA UNIVERSITY  2021/04/20 17:06:19 Benzinga
Advaxis, Inc. (NASDAQ: ADXS ), CEO Ken Berlin presented at the Benzinga Biotech Small-Cap Conference on March 24, 2021. Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, is making new waves as it takes definitive steps to prove that the company is “no longer your grandfather’s Advaxis,” according to company CEO Ken Berlin. Among Advaxis’s new steps is an agreement with the Columbia University Irving Medical Center to fund a Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The company has also announced new data relating to developing a novel flow immunophenotyping assay to accurately evaluate total PD-1 expression as a pharmacodynamic marker during PD-1 blockade. It highlighted translational data demonstrating immune responses correlated to observed clinical benefit from Advaxis’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA®. The report was presented as a poster at this year’s American Association for Cancer Research (AACR) annual meeting.
   Advaxis (NASDAQ:ADXS) Issues Quarterly Earnings Results  2021/03/19 05:14:42 Daily Political
Advaxis (NASDAQ:ADXS) posted its earnings results on Tuesday. The biotechnology company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.10, MarketWatch Earnings reports. Advaxis had a negative net margin of 13,144.62% and a negative return on equity of 81.49%. NASDAQ ADXS opened at $0.84 on Friday. The company […]
   Advaxis Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis  2021/03/11 15:17:00 Stock Market Daily
Advaxis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Cancer Immunotherapy Market Analysis Focusing on Top Key Players - F. Hoffmann-La Roche AG, Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc  2021/03/05 15:43:34 OpenPR
The "Global Cancer Immunotherapy Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the cancer immunotherapy market
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   Advaxis (NASDAQ:ADXS) Issues Quarterly Earnings Results  2021/03/19 05:14:42 Daily Political
Advaxis (NASDAQ:ADXS) posted its earnings results on Tuesday. The biotechnology company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.10, MarketWatch Earnings reports. Advaxis had a negative net margin of 13,144.62% and a negative return on equity of 81.49%. NASDAQ ADXS opened at $0.84 on Friday. The company […]
   Advaxis Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis  2021/03/11 15:17:00 Stock Market Daily
Advaxis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Cancer Immunotherapy Market Analysis Focusing on Top Key Players - F. Hoffmann-La Roche AG, Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc  2021/03/05 15:43:34 OpenPR
The "Global Cancer Immunotherapy Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the cancer immunotherapy market
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
   Advaxis Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis  2021/03/11 15:17:00 Stock Market Daily
Advaxis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Cancer Immunotherapy Market Analysis Focusing on Top Key Players - F. Hoffmann-La Roche AG, Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc  2021/03/05 15:43:34 OpenPR
The "Global Cancer Immunotherapy Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the cancer immunotherapy market
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
   Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies | MarketScreener  2021/01/19 13:01:07 MarketScreener
PRINCETON, N.J., Jan. 19, 2021 -- Advaxis, Inc. , a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that… | January 19, 2021

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アドバクシス ADXS Advaxis Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)